Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $239.56 -2.42%
Revenue Growth %: +15.3%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +15.3%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($2.43), $0.42 worse than the analyst estimate of ($2.01). Revenue for the quarter came in at $2.07 million versus the consensus estimate of $18.23 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Anthropic delays planned IPO from October to November - WSJ
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
